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Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyro-sine kinase used in the treatment of B-cell malignancies. They bindirreversibly to cysteine 481 of Bruton tyrosine kinase, blocking
autophosphorylation on tyrosine 223 and phosphorylation of down-
stream substrates including phospholipase C-g2. In the present study, we
demonstrate that concentrations of ibrutinib and acalabrutinib that block
Bruton tyrosine kinase activity, as shown by loss of phosphorylation at
tyrosine 223 and phospholipase C-g2, delay but do not block aggregation
in response to a maximally-effective concentration of collagen-related
peptide or collagen. In contrast, 10- to 20-fold higher concentrations of
ibrutinib or acalabrutinib block platelet aggregation in response to glyco-
protein VI agonists. Ex vivo studies on patients treated with ibrutinib, but
not acalabrutinib, showed a reduction of platelet aggregation in response
to collagen-related peptide indicating that the clinical dose of ibrutinib
but not acalabrutinib is supramaximal for Bruton tyrosine kinase block-
ade. Unexpectedly, low concentrations of ibrutinib inhibited aggregation
in response to collagen-related peptide in patients deficient in Bruton
tyrosine kinase. The increased bleeding seen with ibrutinib over acal-
abrutinib is due to off-target actions of ibrutinib that occur because of
unfavorable pharmacodynamics.
Introduction
The major physiological ligands that activate platelets in hemostasis and throm-
bosis signal through G protein-coupled and tyrosine kinase-linked receptors. The
former includes receptors for thrombin (PAR1, PAR4), thromboxane A2 (TP) and
ADP (P2Y1, P2Y12), and the latter receptors for collagen/fibrin (glycoprotein VI:
GPVI), podoplanin (CLEC-2), von Willebrand factor (GPIb-IX-V) and fibrinogen
(integrin αIIbβ3).1,2
GPVI is a receptor for collagen and fibrin which forms a complex with the Fc
receptor g-chain (FcRg).2-4 GPVI triggers powerful platelet activation through Src,
Syk and Tec family tyrosine kinases leading to activation of phospholipase C-g2
(PLCg2).5 GPVI is expressed exclusively on platelets and the platelet precursor cell,
the megakaryocyte.6 Mice deficient in GPVI have a minor increase in tail bleeding
times but fail to form occlusive thrombi in a FeCl3 injury arterial thrombosis assay.7
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ABSTRACT
Patients homozygous for an insertion that introduces a
stop codon and prevents expression of the immunoglobu-
lin receptor on the platelet surface have a relatively mild
bleeding diathesis,8 although there are too few of such
individuals  to determine whether they are protected from
thrombosis. 
Bruton tyrosine kinase (Btk) is a member of the Tec fam-
ily of tyrosine kinases and mediates phosphorylation and
activation of PLCg2 downstream of GPVI and the B-cell
antigen receptor. The irreversible Btk inhibitor ibrutinib
has been introduced into the clinic for treatment of B-cell
malignancies but has been reported to increase rates of
major hemorrhage in a subgroup of patients.9,10 The
increase in bleeding has been attributed to a loss of
platelet activation by GPVI11-13 and GPIb,11 with the inhibi-
tion of the two receptors having been shown to corre-
late.14
In contrast to ibrutinib-treated subjects, patients with X-
linked agammaglobulinemia (XLA) do not bleed exces-
sively.15 XLA is caused by mutations in the BTK gene
which result in a loss or reduction of Btk expression, or
expression of a non-functional protein. A potential expla-
nation for this difference in bleeding propensity is that
ibrutinib blocks activation of platelets by both Btk and the
closely related kinase Tec. Tec is expressed in human and
mouse platelets, and has been shown to support PLCg2
activation in mouse platelets.16 Interestingly, major hemor-
rhage is not seen in patients treated with the structurally
related Btk inhibitor, acalabrutinib, despite this also
inhibiting Btk by covalent modification of C481.9,17 It has
been postulated that this is due to its greater selectivity for
Btk over Tec in comparison to ibrutinib.17,18
In the present study we compared the inhibitory effects
of ibrutinib and acalabrutinib on platelet activation and
protein phosphorylation by GPVI alongside ex vivo studies
on patients prescribed the two inhibitors, as well as on
XLA patients.
Methods
Reagents
Details on the source of reagents and chemical analyses can be
found in the Online Supplementary Information. 
Light transmission aggregometry
Aggregation was measured in siliconized glass vials at 37°C in a
Model 700 aggregometer (ChronoLog, Havertown, PA, USA) with
stirring at 1200 rpm. Platelets were warmed to 37°C for 5 min
before the experiments. Platelets were pre-incubated with ibruti-
nib, acalabrutinib or dimethyl sulfoxide (DMSO) vehicle for 5 min
prior to agonist addition unless otherwise stated. Results were
averaged and the half maximal inhibitory concentration (IC50) val-
ues were calculated from these data.
Protein phosphorylation
Washed platelets were pre-treated with 9 mM eptifibatide to
block integrin αIIbβ3 activation. Agonists were added while stir-
ring at 1200 rpm in an aggregometer at 37°C for 180 s unless oth-
erwise stated. The platelets were stimulated in the presence of
ibrutinib (17 nM - 7 mM), acalabrutinib (50 nM – 200 mM) or vehi-
cle (DMSO). For whole cell lysate experiments, activation was ter-
minated with 5X SDS reducing sample buffer. For immunoprecip-
itation, 8x108/mL platelets were used and reactions were terminat-
ed by addition of 2X ice-cold Nonidet P-40 lysis buffer containing
the protease inhibitors sodium orthovanadate (5 mM), leupeptin
(10 mg/mL), AEBSF (200 mg/mL), aprotinin (10 mg/mL) and pep-
statin (1 mg/mL). Platelet lysates were precleared, and detergent-
insoluble debris was discarded. An aliquot was dissolved with
SDS sample buffer for detection of total tyrosine phosphorylation.
Lysates were incubated with either the indicated antibodies and
protein A- or protein G-Sepharose. Lysates were separated by
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE), electro-transferred, and western blotted. Western blots
were imaged using ECL autoradiography film. In order to analyze
levels of phosphorylation, western blot films were scanned and
band intensity measured using ImageJ 1.5 with values normalized
to basal levels. Results were averaged and IC50 values were calcu-
lated from these data.
Other
Details on the methods for blood sampling, platelet preparation,
granule release, [Ca2+]i mobilization, measurement of platelet
adhesion under flow, cell lines, plasmids, transfections and the
luciferase assay can be found in the Online Supplementary
Information.
Statistical analysis
All data are presented as mean ± standard error of the mean
(SEM) with statistical significance taken as P<0.05 unless other-
wise stated. Statistical analyses, unless otherwise specified, were
performed using one-way analysis of variance (ANOVA) with a
Bonferroni post-test. Ex vivo platelet aggregation was determined
by optical densities, which were compared using a one-way
ANOVA with the Tukey multiple comparison test. Correlations of
aggregation with tyrosine phosphorylation were assessed using
the Pearson correlation coefficient. IC50 values were analyzed
using the Welch t-test. All statistical analyses were performed
using GraphPad Prism 7.
Ethical approval
Ethical approval for collecting blood from patients and healthy
volunteers was granted by the National Research Ethics Service
(10/H1206/58) and Birmingham University Internal Ethical
Review (ERN_11-0175), respectively. Work on HLA patients has
ethical approval via the University of Birmingham HBRC 16-251
Amendment 1.
Results
Inhibition of GPVI-induced platelet aggregation by high
concentrations of ibrutinib is reversible 
Ibrutinib is 97% bound to plasma proteins and unbound
levels reach approximately 0.5 mM in patients.11 At this
concentration, ibrutinib has been shown to block GPVI-
induced platelet aggregation.12,19 If this is due to inhibition
of Btk and other Tec kinases then the inhibition should be
irreversible and time-dependent (i.e. inhibition should
increase with time). To test this, platelets were treated
with a concentration of ibrutinib that causes complete
inhibition of GPVI-mediated aggregation in washed
platelets before washout of ibrutinib and stimulation with
the GPVI-specific agonist collagen-related peptide (CRP).
Platelets showed almost full recovery on washout demon-
strating that the inhibitory effect is not due solely to cova-
lent modification of Btk or Tec (Figure 1A,B). In support of
this, incubation of washed platelets with a high concentra-
tion of ibrutinib (700 nM)  for ≥30 s was sufficient to block
aggregation in response to a high dose of CRP (Figure 1C).
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However, at a lower concentration, ibrutinib (70 nM)
caused a time-dependent delay in aggregation in response
to a high concentration of CRP, which was apparent at
incubation times of ≥5 min (Figures 1D and 2Ai). This con-
centration of ibrutinib also caused a reduced response to a
sub-maximal concentration of CRP (Online Supplementary
Figure S2A). The time-dependent delay is consistent with
an irreversible action and contrasts with the rapid onset of
inhibition observed at the high concentration of ibrutinib.
A similar set of observations was seen in washed platelets
stimulated by collagen (Online Supplementary Figure S1A).
Similar results were also seen in the presence of 0.3%
bovine serum albumin, which was used in case the results
were influenced by adsorption of ibrutinib to the surface of
the aggregometer tube (Online Supplementary Figure S1B).
Platelet secretion and Ca2+ mobilization play key roles in
platelet activation. Consistent with the results for aggrega-
tion, low (70 nM) and high (700 nM) concentrations of
ibrutinib had, respectively, no effect or blocked ATP secre-
tion in response to a high concentration of CRP (Figure
2Bi, 2Biii). Similarly, the peak Ca2+ concentration follow-
ing administration of a high concentration of CRP was not
altered in the presence of a low concentration of ibrutinib
(70 nM) but was markedly reduced by a high concentra-
tion (700 nM). The dose-response curve for inhibition of
aggregation was similar to that for loss of Ca2+ mobiliza-
tion (Figure 2Bii, 2Biii) and was not affected by the pres-
ence of the cyclooxygenase inhibitor indomethacin
(Online Supplementary Figure S1D). There was no statistical
difference between the IC50 of ibrutinib for secretion,
Effects of Btk inhibitors on platelet activation
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Figure 1. Increasing ibrutinib incubation time has no effect on degree of inhibition of platelet
aggregation and this inhibition is reversed by washing. (A) Representative traces of washed
platelets at 4x108/mL stimulated with CRP (10 mg/mL for 180 s). Prior to addition of the agonist,
platelets were pre-incubated with either ibrutinib or vehicle (DMSO) for 5 min. Alongside, washed
platelets at 4x108/mL identically treated with either ibrutinib or vehicle were washed twice in Tyrode
buffer and platelets resuspended to 4x108/mL; platelets were then stimulated with CRP (10 mg/mL
for 180 s). The data shown are representative of three identical experiments. (B) Mean data for (A)
(n=3) analyzed with one-way ANOVA. Results are shown as mean ± SEM. *P<0.05. (C) Washed
platelets (4x108/mL) were incubated with ibrutinib or vehicle (DMSO) for 30 s - 60 min before being
stimulated with CRP (10 mg/mL). The optical density (OD) of platelet suspensions was measured in
a ChronoLog Model 700 aggregometer with stirring at 1200 rpm. Traces representative of three
similar experiments are shown. (D) Delay in aggregation seen with ibrutinib-treated washed
platelets (n=3) analyzed with one-way ANOVA. Results are shown as mean ± SEM. *P<0.05. 
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aggregation or Ca2+ mobilization.
Taken together these results show that ibrutinib has
two distinct effects on platelet activation by CRP. At a low
concentration (70 nM), ibrutinib delays but does not
inhibit activation, whereas at a 10-fold higher concentra-
tion of ibrutinib (700 nM) activation is blocked. The latter
action is reversible indicating that it is not mediated by
covalent modification of Btk or other Tec kinases.
Low-dose ibrutinib blocks Btk but not Tec 
The concentration-response curve to ibrutinib on tyro-
sine phosphorylation was investigated in washed platelets
in the same conditions as for the platelet function studies
above. CRP induced robust tyrosine phosphorylation in
whole cell lysates which was dose-dependently inhibited
by ibrutinib. Correspondingly with the results for aggrega-
tion, this inhibitory effect of ibrutinib on global tyrosine
phosphorylation was also reversible on washout (Figure
3Ai). Using phosphospecific antibodies, we were able to
see that the inhibition of Src pY418 (which lies upstream
of Btk) was also reversible but that autophosphorylation
of Btk at pY223 and Btk substrates PLCg2 pY753 and
pY121711,20 was irreversible (Figure 3Ai-ii).
A detailed analysis of the dose response to ibrutinib on
a wider range of proteins in the GPVI signaling cascade
was investigated using further phosphospecific antibodies
(Figure 3Bi). Autophosphorylation of Btk and downstream
PLCg2 was reduced to basal levels by a low dose of ibru-
tinib (70 nM) (Figure 3Bii). In contrast, phosphorylation of
Btk on Y551, which is mediated by Src family kinases,21
and proteins that lie upstream of Btk, namely Src Y418,
Syk Y525/6, SLP-76 Y145 and LAT Y200, was not altered
(Figure 3Biii-iv). Inhibition of phosphorylation of Src on its
activation site, Y418, was observed at a 10-fold higher
concentration of ibrutinib (Figure 3Biv) and was shown to
correlate with inhibition of aggregation (Pearson correla-
P.L.R. Nicolson et al.
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Figure 2. Ibrutinib dose-dependently inhibits glycoprotein VI-mediated platelet aggregation,
ATP secretion and Ca2+ mobilization. (A) (i) Representative traces showing the effect of increas-
ing doses of in vitro ibrutinib incubated for 5 min with washed platelets at 4x108/mL.  (ii)
Ibrutinib dose-response curves in washed platelets (n=7). (B) Representative traces showing the
effect of increasing doses of in vitro ibrutinib incubated with washed platelets at 4x108/mL for
5 min on (i) ATP secretion and (ii) Ca2+ mobilization in response to stimulation with CRP (10
mg/mL) for 180 s. (iii) Ibrutinib dose-response curves in washed platelets on ATP secretion (n=3)
and Ca2+ mobilization (n=3). The dose-response curve for inhibition of washed platelet aggrega-
tion from (Aiii) is shown as a dotted line to enable comparison. Results are shown as mean ±
SEM. All experiments were stimulated with CRP (10 mg/mL). For comparison of IC50: ns = non-
significant. 
Bi Bii
Biii
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Figure 3. Ibrutinib dose-dependently inhibits glycoprotein VI-mediated signaling. (A) Eptifibatide (9 mM)-treated washed human platelets (4×108/mL) were stimulat-
ed with CRP (10 mg/mL for 180 s) followed by lysis with 5X SDS reducing sample buffer. Prior to addition of agonist, platelets were pre-incubated with either ibrutinib
or vehicle (DMSO). Some platelets underwent two further washing steps prior to addition of agonist. (i) Whole cell lysates were then separated by SDS-PAGE and
western blotted with the stated antibodies for whole cell phosphorylation, kinases and proteins downstream of GPVI. Blots are representative of three experiments.
(ii) Percentage tyrosine phosphorylation as compared to that of non-washed vehicle platelets was measured and is represented as the mean ± SEM of three identical
experiments. (Bi) Washed platelets were treated as in (A) but with a wider range of ibrutinib doses. (ii - iv) The percentage of tyrosine phosphorylation as compared
to that of vehicle-treated platelets was measured and is represented as the mean ± SEM of four identical experiments. The dose-response curve for inhibition of
washed platelet aggregation from Figure 2Aii is shown as a dotted line to enable comparison. (C) Eptifibatide (9 mM)-treated washed human platelets (8×108/mL)
were stimulated with CRP (10 mg/mL for 180 s) followed by lysis with 2X ice cold lysis sample buffer. Lysates were pre-cleared and Tec was immunoprecipitated
before addition of SDS reducing sample buffer and separation by SDS-PAGE and western blotted with the anti-pY antibody 4G10. Membranes were stripped and then
reprobed with the pan-Tec antibody. (i) The trace is representative of three identical experiments. (ii) The percentage of tyrosine phosphorylation as compared to that
of vehicle-treated platelets was measured and is represented as the mean ± SEM of three identical experiments. *P<0.05. ns = non-significant.
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tion coefficient 0.959). Inhibition of whole cell phospho-
rylation and phosphorylation of Syk Y525/6, SLP-76 Y145,
Btk Y551 and LAT Y200 was seen at a 7 mM dose of ibru-
tinib which is 10-fold higher than the maximal concentra-
tion in patients (Figure 3Bii, 3Biii). The IC50 values for each
phosphorylation event, when they could be calculated, are
included in Online Supplementary Table S1. Blockade of Btk
pY223 and PLCg2 phosphorylation by 70 nM ibrutinib
was also observed with lower concentrations of CRP or in
the absence of the integrin αIIbβ3 blocker, eptifibatide
(Online Supplementary Figures S2Aiv and S2B). There was
no significant increase in phosphorylation of PLCg2 up to
180 s in response to CRP in the presence of 70 nM ibruti-
nib (Online Supplementary Figure S2Ci-iii). 
Due to the absence of phosphospecific antibodies for
the Btk-related Tec family kinase, Tec, the effect of ibruti-
nib on Tec phosphorylation was investigated following
immunoprecipitation and re-probing with the antiphos-
photyrosine monoclonal antibody 4G10. The effect of
ibrutinib was biphasic with partial blockade at 170 nM
and full blockade observed at 7 mM (Figure 3C). 
These results demonstrate that a concentration of 70
nM ibrutinib is sufficient to block Btk at its autophospho-
rylation site and on PLCg2 on Y753, Y759 and Y1217 and
that this effect is irreversible. At this concentration of ibru-
tinib, aggregation in response to a high concentration of
CRP is delayed but is not blocked. At a 10- to 20-fold high-
er concentration, ibrutinib reversibly blocks aggregation in
parallel with reversible loss of phosphorylation of Src on
Y418. Reversible inhibition of tyrosine phosphorylation of
other proteins is seen at a 100-fold higher concentration
than that required for blockade of Btk. Ibrutinib causes
biphasic inhibition of phosphorylation of Tec, with inhibi-
tion occurring at 3- to 5-fold higher concentrations than
those required to block phosphorylation of Btk on Y223,
and full blockade at a 100-fold higher concentration.
These results are consistent with loss of Tec autophospho-
rylation at 170 nM of ibrutinib and loss of phosphoryla-
tion on the activation site by higher concentrations.
Low-dose ibrutinib has no effect on platelet adhesion
and aggregation in response to collagen under flow
conditions
The relevance of the observation that aggregation is
delayed but not blocked in response to high concentra-
tions of CRP and collagen was addressed using flow stud-
ies in which GPVI functions in conjunction with other
tyrosine kinase-linked receptors that also signal via Btk,
P.L.R. Nicolson et al.
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Figure 4. A low dose of ibrutinib has no effect on platelet adhesion to collagen under flow. (A) Washed platelets (10x108/mL) were incubated with ibrutinib or vehicle
(DMSO) for 5 min and stimulated with CRP (10 mg/mL). (i) Representative trace and (ii) mean data from three identical experiments show a characteristic delay associ-
ated with inhibition of Btk autophosphorylation. (B) Platelets were reconstituted with autologous red blood cells and platelet-poor plasma and flowed at arterial shear
over collagen-coated microcapillaries for 3 min before being fixed and imaged. (i) Representative differential interference contrast images are shown. (ii) Platelet cover-
age as a percentage of values for vehicle-treated platelets was calculated and is shown as mean ± SEM from three identical experiments. *P<0.05, ns: non-significant.
namely GPIb and integrin αIIbβ3. To ensure that a known
degree of Btk blockade was achieved, washed platelets
were incubated with ibrutinib at a concentration sufficient
to fully and irreversibly inhibit Btk kinase activity (70 nM).
Inhibition of Btk autophosphorylation was confirmed by
a delay in aggregation in response to CRP (Figure 4A) and
by measurement of phosphorylation (data not shown).
Following incubation, platelets were reconstituted with
autologous red blood cells and platelet-poor plasma and
flowed over collagen at arterial shear rates. Adhesion of
Effects of Btk inhibitors on platelet activation
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Figure 5. Patients with X-linked agammaglobulinemia, who lack Btk expression are more sensitive than healthy donors to ibrutinib inhibition of glycoprotein VI-mediated
platelet aggregation. Ibrutinib, but not acalabrutinib, blocks glycoprotein VI-mediated platelet aggregation ex vivo.  (A) Citrated blood was taken from XLA patients. (i)
Whole cell lysates were then separated by SDS-PAGE and western blot with the polyclonal N-terminal Btk antibody. Platelet-rich plasma (PRP) from XLA patients was stim-
ulated with CRP (10 mg/mL) for 180 s. (ii) A representative aggregation trace of XLA patients or healthy donor (HD). (iii) Ibrutinib dose-response curves in washed platelets
of XLA patients (n=4). Healthy donor responses from Figure 2Aiii are shown as a dotted line for comparison. (iv) Whole cell lysates were then separated by SDS-PAGE and
western blotted with the phosphospecific antibody to PLCg2 pY1217 (n=3). The aggregation curve for XLA patients is shown as a dotted line for comparison. (B) Patients
taking ibrutinib 420 mg once daily, acalabrutinib 100 mg twice daily or a control chemotherapy regime of fludarabine (25 mg/m2 IV days 1-3), cyclophosphamide (250
mg/m2 IV days 1-3) and rituximab (375 mg/m2 IV day 1) (FCR) had citrated blood taken on day 28 of the treatment cycle (2-3 h after the dose of Btk inhibitor). PRP from
this blood was then stimulated with CRP (10 mg/mL) for 180 s. (i) A representative trace. (ii) Mean and SEM from five, nine and three patients for FCR, ibrutinib and acal-
abrutinib respectively. (iii) Comparison of platelet counts in PRP from all groups of patients. Statistical analysis was performed using a one-way ANOVA with the Tukey mul-
tiple comparisons test, *P<0.05, ns=not significant. (iv) A representative western blot from eptifibatide (9 mM)-treated washed platelets (4×108/mL) from the same patients
stimulated with CRP (10 mg/mL for 180 s) followed by lysis with 5X SDS sample buffer and probed with Btk pY223 and PLCg2 pY1217 phosphospecific antibody. 
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ibrutinib-treated platelets was unchanged when compared
to that of vehicle-treated platelets (Figure 4B).
Btk-specific concentrations of ibrutinib block GPVI
mediated aggregation in patients with X-linked 
agammaglobulinemia
The B-cell immunodeficiency XLA is caused by muta-
tions in the BTK gene. Using knowledge of patients’ muta-
tions (Online Supplementary Table S2), and an antibody to
the N-terminus of Btk, we selected unrelated patients lack-
ing Btk protein to test for off-target effects of ibrutinib
(Figure 5Ai). Strikingly, the concentration-response curve
for inhibition of CRP-induced aggregation by ibrutinib
was shifted to the left in the XLA patients when compared
to that of the healthy donors (Figure 5Aii-iii), whereas the
curve for inhibition of PLCg2 phosphorylation was
unchanged (Figure 5Aiv). Since the only known difference
between XLA patients and controls is the absence of Btk,
this demonstrates an off-target effect of ibrutinib that was
unmasked in the absence of Btk protein. This off-target
action occurred over a similar concentration range to that
required for inhibition of Btk. The GPCR agonists ADP
and PAR1 peptide stimulated robust aggregation in XLA
patients, as previously demonstrated16 (data not shown).
One possible explanation for the increased sensitivity of
XLA patients to ibrutinib relative to controls is that Btk
also functions as an adapter protein in the GPVI signaling
pathway (as the only known difference in these two
groups is Btk protein). To investigate this, we transfected
Btk-deficient DT40 chicken B cells with GPVI and its sig-
naling partner, FcRg, in the presence of wild-type (WT) or
kinase-dead (KD) Btk. Importantly, these cells express
PLCg2 but do not express other Tec family kinases.22,23 The
K430E mutant of Btk has been previously reported to lack
kinase activity.24 Cells lacking Btk or GPVI were unrespon-
sive to collagen. Cells transfected with WT or KD Btk
reconstituted NFAT signaling to a similar degree (Figure
6A,B), demonstrating that Btk also functions as an adapter
protein in the GPVI signaling pathway. A low dose of
ibrutinib had no effect on cells transfected with WT or KD
Btk whereas a high dose of ibrutinib blocked NFAT signal-
ing in both WT and KD transfected cells (Figure 6C).
Together these results demonstrate that Btk functions as
an adapter protein, as well as a kinase, in XLA platelets
and in transfected DT40 cells.
Acalabrutinib inhibits Btk Y223 phosphorylation and
platelet aggregation, secretion and Ca2+ mobilization
by glycoprotein VI 
Studies were extended to a second-generation Btk
inhibitor, acalabrutinib, which, like ibrutinib, irreversibly
binds to Btk at C481 and is highly plasma protein-bound.
Acalabrutinib has a higher selectivity over other tyrosine
kinases relative to ibrutinib, including Src, Syk and Tec,25
but a 5-fold lower IC50 for Btk.17 In patients the mean peak
free drug concentration of acalabrutinib is 1.3 mM.17
Acalabrutinib has a similar, dose-dependent effect on
platelet aggregation to that of ibrutinib. At a concentration
of 2 mM in washed platelets, acalabrutinib induced a slight
delay in aggregation (Online Supplementary Figure S3A) but
had no effect on the overall magnitude of response (Figure
7Aii). The difference in the dose-dependency relative to
ibrutinib is consistent with the lower IC50 of acalabrutinib
for Btk. Similar to ibrutinib, inhibition of platelet aggrega-
tion by CRP occurs at acalabrutinib concentrations that
are one order of magnitude higher than those which cause
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Figure 6. Kinase-dead Btk is sufficient
for glycoprotein VI signaling. Btk-defi-
cient DT40 cells were transfected with
either wild-type (WT) or kinase-dead
(KD) Btk with or without GPVI/FcRg. All
cells were transfected with a NFAT-
luciferase reporter plasmid. Cells were
stimulated with collagen (10 mg/mL) in
the presence of serum. (A) Luciferase
activity was measured and is shown as
mean ± SEM of five identical experi-
ments. (B) Representative western blot
showing equal Btk expression in WT
and KD-transfected cells. (C) Cells were
stimulated with collagen (10 mg/mL) in
the presence or absence of ibrutinib
(0.5 mM – 10 mM). Serum was excluded
during stimulation to avoid plasma
binding of the drugs. Luciferase activity
between vehicle and drug-treated sam-
ples was measured and is shown as the
mean ± SEM of three independent
experiments. *P<0.05, **P<0.01. 
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Figure 7. Acalabrutinib dose-dependently inhibits glycoprotein VI-mediated signaling.  (A) Eptifibatide (9 mM)-treated washed human platelets (4×108/mL) were stimu-
lated with CRP (10 mg/mL for 180 s) followed by lysis with 5X SDS reducing sample buffer. Prior to addition of agonist, platelets were pre-incubated with either acalabru-
tinib or vehicle (DMSO). (i) Whole cell lysates were then separated by SDS-PAGE and western blot with the stated antibodies for whole cell phosphorylation, kinases and
proteins downstream of GPVI. Blots are representative of three experiments. (ii - iv) The percentage of tyrosine phosphorylation as compared to that of vehicle-treated
platelets was measured and is represented as the mean ± SEM of three identical experiments. The dose-response curve for inhibition of aggregation from Online
Supplementary Figure S3D is shown as a dotted line to enable comparison. (B) Eptifibatide (9 mM)-treated washed human platelets (8×108/mL) were stimulated with
CRP (10 mg/mL for 180 s) followed by lysis with 2X ice cold lysis sample buffer. Lysates were precleared and Tec was immunoprecipitated before addition of SDS reducing
sample buffer and separation by SDS-PAGE and western blot with the anti-pY antibody 4G10. Membranes were stripped and reprobed with the pan-Tec antibody. The
trace is representative of three identical experiments. (C) Btk-deficient DT40 cells were transfected with either wild-type (WT) or kinase-dead (KD) Btk with or without
GPVI/FcRg. All cells were transfected with a NFAT-luciferase reporter plasmid. Cells were stimulated with collagen (10 mg/mL) in the presence or absence of acalabrutinib
(0.5-10 mM). Serum was excluded during stimulation to avoid plasma binding of the drugs. Luciferase activity between vehicle and drug-treated samples was measured
and is shown as the mean ± SEM of three independent experiments. ns = non-significant. 
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a delay in aggregation; and the curves for inhibition of
ATP secretion and Ca2+ mobilization lie slightly to the left
of that for aggregation (Online Supplementary Figure S3A-
E). As with ibrutinib, acalabrutinib blocked tyrosine phos-
phorylation of Btk on Y223 and PLCg2 on Y759 and Y1217
at a concentration (2 mM) that caused a delay in onset but
no reduction in aggregation (Figure 7Ai,ii). Higher concen-
trations of acalabrutinib (up to 200 mM) had no effect on
phosphorylation of Src Y418, Syk Y525/6 and LAT Y200
but caused a small reduction in phosphorylation of Btk
Y551 and SLP-76 Y145 (Figure 7Ai,iii-iv). Interestingly,
acalabrutinib also caused a biphasic inhibition of Tec
phosphorylation with partial inhibition observed at
approximately 1 mM and full blockade at 200 mM (Figure
7B). The IC50 values for each phosphorylation event are
included in Online Supplementary Table S1. Concentrations
of acalabrutinib that blocked phosphorylation of Btk in
platelets had no effect on NFAT activation by CRP in
DT40 cells transfected with WT or KD Btk (Figure 7C).
Allowing for the fact that acalabrutinib has a 5-fold
lower potency for Btk, these results are in line with those
for ibrutinib.
Glycoprotein VI-mediated platelet aggregation is
blocked ex vivo in patients taking ibrutinib, but not
acalabrutinib
We investigated the effect of ibrutinib and acalabrutinib
in patients with chronic lymphoid leukemia (CLL) taking
ibrutinib 420 mg once daily, acalabrutinib 100 mg twice
daily or a non-Btk targeting control chemotherapy regi-
men. GPVI-induced platelet aggregation was blocked in
the platelet-rich plasma of patients taking ibrutinib but
was not blocked in patients taking acalabrutinib or in the
control group despite complete inhibition of autophos-
phorylation of Btk pY223 and its downstream substrate
PLCg2 at pY1217 by both inhibitors (Figure 5Bi-iv).
Platelet aggregation induced by the GPCR agonists, ADP
and PAR1 peptide, was not altered in the patients taking
either inhibitor (data not shown).
Discussion
In this study we show that (i) irreversible blockade of
Btk by ibrutinib and acalabrutinib delays but does not
block the platelet aggregation induced by high concentra-
tions of GPVI agonists; (ii) blockade of GPVI-mediated
aggregation by ibrutinib and acalabrutinib occurs at a con-
centration one to two orders of magnitude higher than is
required to block Btk due to an off-target action which is
reversible; (iii) the ratio between inhibition of Btk kinase
activity and platelet aggregation induced by GPVI is the
same for ibrutinib and acalabrutinib; (iv) clinically relevant
concentrations of ibrutinib but not acalabrutinib block
activation of platelets by GPVI; (v) platelet adhesion and
aggregation under flow conditions is maintained follow-
ing inhibition of Btk; (vi) Btk supports platelet activation
by GPVI by acting as an adapter protein and as a tyrosine
kinase; and (vii) ibrutinib blocks platelet aggregation in
XLA patients at concentrations that block Btk. 
These results show that platelets, in which Btk kinase
function and downstream PLCg2 phosphorylation have
been blocked, have a slight delay in aggregation in
response to high concentrations of GPVI ligands, while
platelet adhesion and aggregation under arterial flow con-
ditions are unaltered. These observations, together with
reports that patients with XLA or those treated with acal-
abrutinib do not experience major bleeding,15,17 provide
powerful evidence that inhibition of Btk does not give rise
to major bleeding. The major bleeding observed in
patients treated with ibrutinib relative to acalabrutinib is
due to the differential dosing regimens of the two Btk
inhibitors, with the clinical dose of ibrutinib blocking acti-
vation of platelets by GPVI due to one or more off-target
effects. 
The conclusion that inhibition of Btk does not give rise
to major bleeding on treatment with ibrutinib contrasts
with the conclusion of the studies by Levade et al.11 and
Bye et al.13. Levade et al.11 demonstrated a close correlation
between inhibition of autophosphorylation of Btk at Y223
and aggregation in GPVI-activated platelets. While we are
unable to explain this in the light of the present observa-
tions, we note that Levade et al.11 also reported that phos-
phorylation of PLCg2 at Y753, which is mediated by Btk,
was inhibited at a 10-fold lower concentration of ibrutinib
as is seen in the present study. Bye et al.13 used a single,
supramaximal concentration of ibrutinib which also
blocked Src phosphorylation for their biochemical and
flow-based assays. The determination of full concentra-
tion-response curves in the present study has highlighted
the mismatch between inhibition of Btk and loss of
platelet aggregation, and has provided evidence that the
bleeding diathesis that is seen in some ibrutinib-treated
patients is due to off-target effects. 
An unexpected observation in the present study was
that platelets are able to aggregate in response to a high
dose of CRP despite the absence of detectable PLCg2
phosphorylation. One explanation for this is that Btk also
supports activation of PLCg2 as an adapter protein as
shown by the observation that transfection of KD Btk
restores GPVI signaling in DT40 cells. A similar result has
been previously shown for Btk in B-cell receptor
signaling.24,26 This is in keeping with previous studies
showing that phosphorylation of PLCg2 at Y1217 is not
required for its enzymatic activity in Ramos cells.27
We were surprised to find that platelets from XLA
patients, who lack Btk protein, have increased susceptibil-
ity to ibrutinib relative to platelets from controls. The only
known difference between the XLA patients and controls
in the presence of ibrutinib is the absence of Btk protein,
although this could also change the balance of activatory
and inhibitory phosphorylation within the GPVI signaling
cascade. Furthermore, the absence of Btk renders aggrega-
tion of these platelets critically dependent on PLCg2 phos-
phorylation in contrast to controls. The target for ibrutinib
which gives rise to inhibition of aggregation in the XLA
patients is not known. There are several kinases that are
inhibited by ibrutinib over a similar range of concentra-
tions to that for inhibition of Btk.18 Within this group only
Csk is known to be expressed in platelets.28
We have shown that blockade of GPVI-mediated
platelet aggregation by ibrutinib is reversible, which con-
trasts with the irreversible blockade of Btk and Tec.18 The
reversibility provides evidence that blockade is not medi-
ated by inhibition of Tec family kinases, as was previously
postulated,9,11,17 because Tec also has a cysteine residue in
its ATP binding domain analogous to C481 on Btk. This is
further supported by the observation that ibrutinib-medi-
ated blockade of NFAT signaling in DT40 cells, which lack
Tec, follows a similar pattern as that for platelet aggrega-
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tion; namely no effect at low doses with blockade at high
doses. For ibrutinib, we have shown that inhibition of
aggregation correlates strongly with loss of phosphoryla-
tion at Src Y418. However, this is not altered by acalabru-
tinib demonstrating an as yet unidentified off-target
action. Bye et al.13 also showed that ibrutinib dose-depen-
dently inhibits phosphorylation of Src Y418. However, in
a different study they found that both low-dose ibrutinib
and acalabrutinib potentiated Src Y418 phosphorylation.29
We were not able to replicate this latter finding.
We have shown that, despite acalabrutinib’s more
favorable selectivity to Btk over other Src, Syk and Tec
kinases in in vitro kinase assays, the window between Btk
inhibition and blockade of GPVI-induced aggregation in
vitro is similar to that of ibrutinib. Despite this, acalabru-
tinib, but not ibrutinib, fails to block GPVI-mediated
platelet activation ex vivo. We propose that this is because
of the differential dosing and pharmacodynamics of the
two Btk inhibitors. Acalabrutinib is used at a dose of 1.5
mg/kg twice daily17,30 and ibrutinib at a single daily dose
of 6 mg/kg in CLL or 8 mg/kg in mantle cell lymphoma.
Pharmacokinetic studies have shown that ibrutinib
achieves Btk occupancy of >95% at doses of 2.5 mg/kg
but that doses of 6 mg/kg are required to maintain this
over 24 h.31 Acalabrutinib at 1.5 mg/kg twice daily also
achieves full Btk occupancy over 24 h.17 The peak
unbound plasma concentration of ibrutinib in patients is
0.5 mM11 and that of acalabrutinib 1.3 mM.17 The initial
and terminal half-lives of ibrutinib are 2-3 h and 4-8 h,
respectively.31 The half-life of acalabrutinib is 1 h.17
Despite the peak concentration of acalabrutinib being
approximately 2-fold higher than the concentration of
ibrutinib, the 5-fold lower potency of acalabrutinib as an
inhibitor of Btk30 means that, in potency terms, it is dosed
at a lower level consistent with the lack of inhibition of
GPVI. This implies that ibrutinib could be used at a lower
concentration to achieve Btk blockade. Indeed, there is
retrospective clinical evidence that doses less than 6
mg/kg are as effective as 6 mg/kg for treating CLL32 and a
prospective clinical trial using doses as low as 2.5 mg/kg
is being undertaken.33
It is important to consider the incidence of minor and
major bleeding in patients taking ibrutinib for CLL or at
the higher dose for mantle cell lymphoma. In reported
studies involving patients treated with ibrutinib for man-
tle cell lymphoma, minor and major bleeding was seen in
9-15% and 1-5% of patients, respectively.34-36 In the study
with the largest cohort of patients with mantle cell lym-
phoma, the rate of major hemorrhages was 5%. This is
comparable to the 4-8% major hemorrhage rate seen in
patients taking ibrutinib for CLL.9 Thus, there is no
increase in bleeding rates with higher doses of ibrutinib.
This implies that the inhibitory effect of 420 mg ibrutinib
on platelets is at a physiological maximum.
During the writing of this manuscript, Bye et al. reported
thrombus instability on collagen in a flow adhesion assay
in blood treated in vitrowith high doses of ibrutinib and ex
vivo in patients treated with ibrutinib.29 This is consistent
with our findings that Btk kinase function is not required
for platelet adhesion to collagen under flow, but that off-
target effects of ibrutinib seen with higher doses mediate
this inhibition. They also reported complete blockade of
platelet aggregation in response to supramaximal concen-
trations of collagen in patients receiving ibrutinib or acal-
abrutinib29 in contrast to the findings of this study. Bye et
al. used the Optimul 96-well microtiter assay to measure
aggregation rather than the widely used light transmission
aggregometry. We have shown that Optimul is a more
sensitive assay than light transmission aggregometry.37,38
We suggest that the delay in onset of aggregation
observed using light transmission aggregometry with con-
centrations of ibrutinib or acalabrutinib that just block Btk
manifest as complete blockade in the Optimul assay. Bye
et al. also concluded that the increased bleeding observed
with ibrutinib is due to blockade of Src family kinases
(SFK).29 We agree that bleeding caused by ibrutinib is due
to off-target actions, and that acalabrutinib has a greater
selectively to Btk over SFK relative to ibrutinib. However,
our results show that a similar fold increase in the concen-
tration of ibrutinib and acalabrutinib causes inhibition of
platelet aggregation in response to CRP but without con-
comitant SFK blockade in the acalabrutinib-treated
platelets. Thus, the off-target action of ibrutinib and acal-
abrutinib that inhibits aggregation cannot be explained
solely by differential blockade of SFK.
The results of our study explain the lack of major bleed-
ing side effects experienced by patients taking acalabruti-
nib and suggest that the bleeding side effect of ibrutinib
can potentially be abolished by reducing the dose.
Furthermore, this study also shows that the bleeding
caused by ibrutinib is not due to an irreversible action.
This predicts that the GPVI blockade wears off over a peri-
od of 24 h as the drug is cleared.31 We hypothesize that, in
the event of a major bleed, there may be no need to use
expensive and potentially harmful platelet transfusions to
correct the signaling deficit. Nevertheless, each clinical
scenario should be judged on its own merits and individ-
ual clinicians’ discretion is crucial.
In conclusion, the present study shows that inhibition
of Btk kinase activity causes only partial inhibition of
GPVI signaling in platelets and provides evidence that Btk
supports GPVI signaling by functioning as an adapter pro-
tein as well as a kinase. The excessive bleeding induced by
ibrutinib relative to acalabrutinib is likely to reflect a non-
Tec family kinase off-target inhibitory effect of ibrutinib,
probably on Src.
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